脾氨肽联合匹多莫德辅助治疗儿童哮喘的疗效及其对干扰素调控因子1和信号转导转录活化因子-1表达的影响

Efficacy of Spleen Aminopeptide Combined with Pidotimod in Adjuvant Treatment of Children with Asthma and Its Effects on Expression of Interferon Regulatory Factor 1 and Signal Transducer and Activator of Transcription-1

目的:探讨脾氨肽联合匹多莫德辅助治疗儿童哮喘的效果与机制。方法:选取2020年3月至2021年3月我院儿科诊治的支气管哮喘急性发作期患儿178例,按随机数表法分为观察组和对照组各89例。两组患儿均采用常规治疗与管理,观察组在常规治疗基础上加用脾氨肽和匹多莫德,比较两组患儿疗效,检测治疗前后T淋巴细胞亚群CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)水平,记录临床症状(咳喘、呼吸困难、哮鸣音)消失时间,采用2^(-ΔΔCt)相对定量法分析治疗前后外周血干扰素调控因子1(IRF1)和信号转导转录活化因子-1(STAT1)的相对表达量。结果:观察组总有效率为92.13%,高于对照组的75.28%(P<0.01);观察组咳喘消失时间、呼吸困难消失时间、哮鸣音消失时间均短于对照组(P均<0.01)。两组患儿治疗后CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均高于治疗前,CD8^(+)、IRF1、STAT1水平均低于治疗前,且观察组治疗后CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均高于对照组,CD8^(+)、IRF1、STAT1水平均低于对照组(P均<0.05)。结论:在常规治疗与管理基础上加用脾氨肽和匹多莫德,可改善哮喘患儿的免疫功能,缩短症状消失时间,抑制IRF1、STAT1的表达,从而有效提高治疗效果。

Objective:To probe into the effect and mechanism of spleen aminopeptide combined with pidotimod in the adjuvant treatment of children with asthma.Methods:Totally 178 children with acute attack of bronchial asthma admitted into pediatrics of our hospital from Mar.2020 to Mar.2021 were extracted to be divided into the observation group and the control group via the random number table,with 89 cases in each group.Both groups were treated with conventional treatment and management,and the observation group was additionally given spleen aminopeptide combined with pidotimod.The efficacy of two groups was compared,and the levels of CD3^(+),CD4^(+),CD8^(+) and CD4^(+)/CD8^(+) of T lymphocyte subsets before and after treatment were detected.The disappearance time of clinical symptoms(cough and asthma,dyspnea and wheezing)was recorded.Relative expression levels of interferon regulator factor 1(IRF1)and signal transducer and activator of transcription-1(STAT1)in peripheral blood before and after treatment were analyzed by 2^(-ΔΔCt) relative quantification method.Results:The total effective rate in the observation group was 92.13%,higher than 75.28%in the control group(P<0.05).The disappearance time of cough and asthma,dyspnea and wheezing in the observation group were shorter than those in the control group(P<0.01).After treatment,the levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+) in two groups were higher than those before treatment,the levels of CD8^(+),IRF1,STAT1 were lower than those before treatment,and the levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+) in the observation group were higher than those in the control group after treatment,the levels of CD8^(+),IRF1 and STAT1 were lower than those in the control group(P<0.05).Conclusion:On the basis of routine treatment and management,spleen aminopeptide combined with pidotimod can improve the immune function of children with asthma,shorten the disappearance time of symptoms,inhibit the expression of IRF1 and STAT1,so as to effectively improve the therapeutic effect.